Supporting our observations, the BBB permeability measured by albumin and IgG extravasation was lowered following intravenous administration of AAV‐BR1 in incontinentia pigmenti, which is a genetic disease characterized by BBB disruption, hence counteracting BBB disruption caused by the administration of AAV‐BR1 vectors (Dogbevia et al., 2017; Körbelin et al., 2016). This evidence concerns the gene CXCL11 and hereditary disease.